Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT03260205 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

199

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG: Placebo
DRUG: SPD489 (Lisdexamfetamine dimesylate)
DRUG: SPD489

Sponsor

Shire